116 related articles for article (PubMed ID: 38168678)
1. Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression.
Xiong Z; Tong T; Xie Z; Yu S; Zhuang R; Jia Q; Peng S; Li B; Xie J; Li K; Wu J; Huang H
Biomater Sci; 2024 Jan; 12(3):650-659. PubMed ID: 38168678
[TBL] [Abstract][Full Text] [Related]
2. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
[TBL] [Abstract][Full Text] [Related]
3. Delivery of enzalutamide
Gao Z; Huang J; Xie Z; Xin P; Huang H; Du T; Wu J; Huang H
Biomater Sci; 2022 Sep; 10(18):5187-5196. PubMed ID: 35833529
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells.
Shen Y; TanTai J
Drug Des Devel Ther; 2020; 14():4503-4510. PubMed ID: 33122893
[TBL] [Abstract][Full Text] [Related]
5. p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer.
Garizo AR; Castro F; Martins C; Almeida A; Dias TP; Fernardes F; Barrias CC; Bernardes N; Fialho AM; Sarmento B
J Control Release; 2021 Sep; 337():329-342. PubMed ID: 34311024
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
Ni XL; Chen LX; Zhang H; Yang B; Xu S; Wu M; Liu J; Yang LL; Chen Y; Fu SZ; Wu JB
Drug Deliv; 2017 Nov; 24(1):1501-1512. PubMed ID: 28961023
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
Lai KC; Chueh FS; Hsiao YT; Cheng ZY; Lien JC; Liu KC; Peng SF; Chung JG
Toxicol Appl Pharmacol; 2019 Nov; 382():114734. PubMed ID: 31470033
[TBL] [Abstract][Full Text] [Related]
9. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
10. Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer.
Ota H; Sato H; Mizumoto S; Wakai K; Yoneda K; Yamamoto K; Nakanishi H; Ikeda JI; Sakamoto S; Ichikawa T; Yamada S; Takahashi S; Ikehara Y; Nishihara S
Sci Rep; 2023 Jul; 13(1):11618. PubMed ID: 37463954
[TBL] [Abstract][Full Text] [Related]
11. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
[TBL] [Abstract][Full Text] [Related]
12. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W
Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182
[TBL] [Abstract][Full Text] [Related]
13. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles.
Yugui F; Wang H; Sun D; Zhang X
Biomed Pharmacother; 2019 Jun; 114():108820. PubMed ID: 30951947
[TBL] [Abstract][Full Text] [Related]
15. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
16. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
19. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
[TBL] [Abstract][Full Text] [Related]
20. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
